Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-7479d7b7d-c9gpj Total loading time: 0 Render date: 2024-07-13T13:26:56.410Z Has data issue: false hasContentIssue false

32 - Surgical and Medical Treatment

from PART III - ORGAN-SPECIFIC CANCERS

Published online by Cambridge University Press:  18 May 2010

By
Surena F. Matin
Edited by
Jean-François H. Geschwind  and
Michael C. Soulen
Surena F. Matin
Affiliation:
Associate Professor, Department of Urology M.D. Anderson Cancer Center University of Texas Houston, TX
Jean-François H. Geschwind
Affiliation:
The Johns Hopkins University School of Medicine
Michael C. Soulen
Affiliation:
University of Pennsylvania School of Medicine
Get access

Summary

INCIDENCE AND DIAGNOSIS

Renal cell carcinoma (RCC) is the most common malignancy of the kidney. In 2007, there were more than 51,100 new cases of RCC in the United States, and 12,890 patients died from the disease (1). The incidence of RCC has been on the rise since the latter part of the twentieth century, independent of advances in abdominal imaging that have improved diagnostic potential (2). According to the National Cancer Institute's 1975 to 1995 Surveillance, Epidemiology, and End Results database, this increase has been seen in both women and men and across racial boundaries (3).

RCC is associated with older age and is increasingly diagnosed in patients past the fifth decade of life. In addition to age, the only risk factors for RCC are smoking and tobacco exposure. Other factors that may be associated with a high risk of RCC include obesity, diabetes mellitus, hypertension, diuretic use, high alcohol intake, high fat intake and high red meat intake; however, the causative potential of these factors is yet unproven (4).

The kidney is a well-protected, markedly silent organ. It is sheltered within the rib cage and is often surrounded by a thick rind of fat, and it is innervated to respond to only acute visceral distension. Thus, small renal tumors typically develop asymptomatically. The classic symptoms of RCC are abdominal mass, pain and hematuria. This presentation is rare, but when these symptoms do occur, they are a signal for advanced-stage disease.

Type
Chapter
Information
Interventional Oncology
Principles and Practice
 , pp. 377 - 399
Publisher: Cambridge University Press
Print publication year: 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Jemal, A, Siegel, R, Ward, E, et al. Cancer statistics, 2007. CA Cancer J Clin, 2007; 57(1): 43–66.CrossRefGoogle ScholarPubMed
Lightfoot, N, Conlon, M, Kreiger, N, et al. Impact of noninvasive imaging on increased incidental detection of renal cell carcinoma. Eur Urol, 2000; 37(5): 521–527.CrossRefGoogle ScholarPubMed
Chow, W H, Devesa, S S, Warren, J L, et al. Rising incidence of renal cell cancer in the United States. JAMA, 1999; 281(17): 1628–1631.CrossRefGoogle ScholarPubMed
Murai, M and Oya, M. Renal cell carcinoma: Etiology, incidence and epidemiology. Curr Opin Urol, 2004; 14(4): 229–233.CrossRefGoogle ScholarPubMed
Campbell, R J, Broaddus, S B, and Leadbetter, G W. Staging of renal cell carcinoma: Cost-effectiveness of routine preoperative bone scans. Urology, 1985; 25(3): 326–329.CrossRefGoogle ScholarPubMed
Gold, P J, Fefer, A, and Thompson, J A. Paraneoplastic manifestations of renal cell carcinoma. Semin Urol Oncol, 1996; 14(4): 216–222.Google ScholarPubMed
Kim, H L, Belldegrun, A S, Freitas, D G, et al. Paraneoplastic signs and symptoms of renal cell carcinoma: Implications for prognosis. J Urol, 2003; 170(5): 1742–1746.CrossRefGoogle ScholarPubMed
Rosenblum, S L. Paraneoplastic syndromes associated with renal cell carcinoma. J SC Med Assoc, 1987; 83(7): 375–378.Google ScholarPubMed
Sufrin, G, Chasan, S, Golio, A. Paraneoplastic and serologic syndromes of renal adenocarcinoma. Semin Urol, 1989; 7(3): 158–171.Google ScholarPubMed
Blay, J Y, Rossi, J F, Wijdenes, J, et al. Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int J Cancer, 1997; 72(3): 424–430.3.0.CO;2-R>CrossRefGoogle ScholarPubMed
Hanash, K A. The nonmetastatic hepatic dysfunction syndrome associated with renal cell carcinoma (hypernephroma): Stauffer's syndrome. Prog Clin Biol Res, 1982; 100: 301–316.Google ScholarPubMed
Stauffer, M H. Nephrogenic hepatosplenomegaly. Gastroenterology, 1961; 40: 694.Google Scholar
AJCC Cancer Staging Manual, 6th edition. New York: Springer-Verlag; 2002.
Tokuda, N, Naito, S, Matsuzaki, O, et al. Collecting duct (Bellini duct) renal cell carcinoma: A nationwide survey in Japan. J Urol, 2006; 176(1): 40–43.CrossRefGoogle ScholarPubMed
Davis, C J Jr., Mostofi, F K, and Sesterhenn, I A. Renal medullary carcinoma. The seventh sickle cell nephropathy. Am J Surg Pathol, 1995; 19(1): 1–11.CrossRefGoogle ScholarPubMed
Figenshau, R S, Basler, J W, Ritter, J H, et al. Renal medullary carcinoma. J Urol, 1998; 159(3): 711–713.CrossRefGoogle ScholarPubMed
Avery, R A, Harris, J E, Davis, C J Jr, et al. Renal medullary carcinoma: Clinical and therapeutic aspects of a newly described tumor. Cancer, 1996; 78(1): 128–132.3.0.CO;2-1>CrossRefGoogle ScholarPubMed
Peralta-Venturina, M, Moch, H, Amin, M, et al. Sarcomatoid differentiation in renal cell carcinoma: A study of 101 cases. Am J Surg Pathol, 2001; 25(3): 275–284.CrossRefGoogle ScholarPubMed
Mian, B M, Bhadkamkar, N, Slaton, J W, et al. Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. J Urol, 2002; 167(1): 65–70.CrossRefGoogle ScholarPubMed
Morra, M N and Das, S. Renal oncocytoma: A review of histogenesis, histopathology, diagnosis and treatment. J Urol, 1993; 150(2 Pt 1): 295–302.CrossRefGoogle Scholar
Campbell, S C, Novick, A C, Herts, B, et al. Prospective evaluation of fine needle aspiration of small, solid renal masses: Accuracy and morbidity. Urology, 1997; 50(1): 25–29.CrossRefGoogle ScholarPubMed
Bosniak, M A, Megibow, A J, Hulnick, D H, et al. CT diagnosis of renal angiomyolipoma: The importance of detecting small amounts of fat. AJR Am J Roentgenol, 1988; 151(3): 497–501.CrossRefGoogle ScholarPubMed
Helenon, O, Merran, S, Paraf, F, et al. Unusual fat-containing tumors of the kidney: A diagnostic dilemma. Radiographics, 1997; 17(1): 129–144.CrossRefGoogle ScholarPubMed
Steiner, M S, Goldman, S M, Fishman, E K, et al. The natural history of renal angiomyolipoma. J Urol, 1993; 150(6): 1782–1786.CrossRefGoogle ScholarPubMed
Fazeli-Matin, S and Novick, A C. Nephron-sparing surgery for renal angiomyolipoma. Urology, 1998; 52(4): 577–583.CrossRefGoogle ScholarPubMed
Hamlin, J A, Smith, D C, Taylor, F C, et al. Renal angiomyolipomas: Long-term follow-up of embolization for acute hemorrhage. Can Assoc Radiol J, 1997; 48(3): 191–198.Google ScholarPubMed
Han, Y M, Kim, J K, Roh, B S, et al. Renal angiomyolipoma: Selective arterial embolization – effectiveness and changes in angiomyogenic components in long-term follow-up. Radiology, 1997; 204(1): 65–70.CrossRefGoogle ScholarPubMed
Eble, J N, Amin, M B, and Young, R H. Epithelioid angiomyolipoma of the kidney: A report of five cases with a prominent and diagnostically confusing epithelioid smooth muscle component. Am J Surg Pathol, 1997; 21(10): 1123–1130.CrossRefGoogle ScholarPubMed
Sanchez-Ortiz, R F, Madsen, L T, Bermejo, C E, et al. A renal mass in the setting of a nonrenal malignancy: When is a renal tumor biopsy appropriate?Cancer, 2004; 101(10): 2195–2201.CrossRefGoogle ScholarPubMed
Lonser, R R, Glenn, G M, Walther, M, et al. von Hippel-Lindau disease. Lancet, 2003; 361: 2059–2067.CrossRefGoogle ScholarPubMed
Sweeney, P, El-Naggar, A K, Lin, S H, et al. Biological significance of c-met over expression in papillary renal cell carcinoma. J Urol, 2002; 168(1): 51–55.CrossRefGoogle ScholarPubMed
Zbar, B, Tory, K, Merino, M, et al. Hereditary papillary renal cell carcinoma. J Urol, 1994; 151(3): 561–566.CrossRefGoogle ScholarPubMed
Schmidt, L, Duh, F M, Chen, F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet, 1997; 16(1): 68–73.CrossRefGoogle ScholarPubMed
Linehan, W M, Walther, M M, and Zbar, B. The genetic basis of cancer of the kidney. J Urol, 2003; 170(6 Pt 1): 2163–2172.CrossRefGoogle ScholarPubMed
Birt, A R, Hogg, G R, Dube, W J. Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons. Arch Dermatol, 1977; 113(12): 1674–1677.CrossRefGoogle ScholarPubMed
Nickerson, M, Warren, M, Toro, J, et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell, 2002; 2(2): 157.CrossRefGoogle Scholar
Pavlovich, C P, Walther, M M, Eyler, R A, et al. Renal tumors in the Birt-Hogg-Dube syndrome. Am J Surg Pathol, 2002; 26(12): 1542–1552.CrossRefGoogle ScholarPubMed
Patard, J J, Leray, E, Rioux-Leclercq, N, et al. Prognostic value of histologic subtypes in renal cell carcinoma: A multicenter experience. J Clin Oncol, 2005; 23(12): 2763–2771.CrossRefGoogle ScholarPubMed
Levy, D A, Slaton, J W, Swanson, D A, et al. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol, 1998; 159(4): 1163–1167.CrossRefGoogle ScholarPubMed
Zisman, A, Pantuck, A J, Wieder, J, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol, 2002; 20(23): 4559–4566.CrossRefGoogle ScholarPubMed
Patard, J J, Kim, H L, Lam, J S, et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: An international multicenter study. J Clin Oncol, 2004; 22(16): 3316–3322.CrossRefGoogle ScholarPubMed
Frank, I, Blute, M L, Cheville, J C, et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: The SSIGN score. J Urol, 2002; 168(6): 2395–2400.CrossRefGoogle ScholarPubMed
Ficarra, V, Martignoni, G, Lohse, C, et al. External validation of the Mayo Clinic Stage, Size, Grade and Necrosis (SSIGN) score to predict cancer specific survival using a European series of conventional renal cell carcinoma. J Urol, 2006; 175(4): 1235–1239.CrossRefGoogle Scholar
Sorbellini, M, Kattan, M W, Snyder, M E, et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol, 2005; 173(1): 48–51.CrossRefGoogle ScholarPubMed
Cindolo, L, Patard, J J, Chiodini, P, et al. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: A multicenter European study. Cancer, 2005; 104(7): 1362–1371.CrossRefGoogle ScholarPubMed
Motzer, R J, Mazumdar, M, Bacik, J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol, 1999; 17(8): 2530–2540.CrossRefGoogle ScholarPubMed
Mekhail, T M, Abou-Jawde, R M, Boumerhi, G, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol, 2005; 23(4): 832–841.CrossRefGoogle ScholarPubMed
Bui, M H, Visapaa, H, Seligson, D, et al. Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol, 2004; 171(6 Pt 1): 2461–2466.CrossRefGoogle ScholarPubMed
Kim, H L, Seligson, D, Liu, X, et al. Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol, 2005; 173(5): 1496–1501.CrossRefGoogle ScholarPubMed
Bosniak, M A, Birnbaum, B A, Krinsky, G A, et al. Small renal parenchymal neoplasms: Further observations on growth. Radiology, 1995 Dec.; 197(3): 589–597.CrossRefGoogle Scholar
Volpe, A, Panzarella, T, Rendon, R A, et al. The natural history of incidentally detected small renal masses. Cancer, 2004; 100(4): 738–745.CrossRefGoogle ScholarPubMed
Kassouf, W, Aprikian, A G, Laplante, M, et al. Natural history of renal masses followed expectantly. J Urol, 2004; 171(1): 111–113; discussion, 113.CrossRefGoogle ScholarPubMed
Robson, C J, Churchill, B M, Anderson, W. The results of radical nephrectomy for renal cell carcinoma. Transactions of the American Association of Genito-Urinary Surgeons, 1968; 60: 122–129.Google ScholarPubMed
Robson, C J, Churchill, B M, Anderson, W. The results of radical nephrectomy for renal cell carcinoma. J Urol, 1969; 101(3): 297–301.CrossRefGoogle ScholarPubMed
Skinner, D G, Vermillion, C D, Colvin, R B. The surgical management of renal cell carcinoma. J Urol, 1972; 107(5): 705–710.CrossRefGoogle ScholarPubMed
Sagalowsky, A I, Kadesky, K T, Ewalt, D M, et al. Factors influencing adrenal metastasis in renal cell carcinoma. J Urol, 1994; 151(5): 1181–1184.CrossRefGoogle ScholarPubMed
Shalev, M, Cipolla, B, Guille, F, et al. Is ipsilateral adrenalectomy a necessary component of radical nephrectomy?J Urol, 1995; 153(5): 1415–1417.CrossRefGoogle ScholarPubMed
Kozak, W, Holtl, W, Pummer, K, et al. Adrenalectomy – still a must in radical renal surgery?Brit J Urol, 1996; 77(1): 27–31.CrossRefGoogle Scholar
Kletscher, B A, Qian, J, Bostwick, D G, et al. Prospective analysis of the incidence of ipsilateral adrenal metastasis in localized renal cell carcinoma. J Urol, 1996; 155(6): 1844–1846.CrossRefGoogle ScholarPubMed
Tsui, K H, Shvarts, O, Barbaric, Z, et al. Is adrenalectomy a necessary component of radical nephrectomy? UCLA experience with 511 radical nephrectomies. J Urol, 2000; 163(2): 437–441.CrossRefGoogle ScholarPubMed
Pizzocaro, G, Piva, L, Salvioni, R. Lymph node dissection in radical nephrectomy for renal cell carcinoma: Is it necessary?Eur Urol, 1983; 9(1): 10–12.CrossRefGoogle ScholarPubMed
Tsukamoto, T, Kumamoto, Y, Miyao, N, Yet al. Regional lymph node metastasis in renal cell carcinoma: Incidence, distribution and its relation to other pathological findings. Eur Urol, 1990; 18(2): 88–93.CrossRefGoogle ScholarPubMed
Terrone, C, Guercio, S, Luca, S, et al. The number of lymph nodes examined and staging accuracy in renal cell carcinoma. BJU International, 2003; 91(1): 37–40.CrossRefGoogle ScholarPubMed
Ditonno, P, Traficante, A, Battaglia, M, et al. Role of lymphadenectomy in renal cell carcinoma. Prog Clin Biol Res, 1992; 378: 169–174.Google ScholarPubMed
Blom, J H, Poppel, H, Marechal, J M, et al. Radical nephrectomy with and without lymph node dissection: Preliminary results of the EORTC randomized Phase III protocol 30881. EORTC Genitourinary Group. Eur Urol, 1999; 36(6): 570–575.CrossRefGoogle ScholarPubMed
Pantuck, A J, Zisman, A, Dorey, F, et al. Renal cell carcinoma with retroperitoneal lymph nodes: Role of lymph node dissection. J Urol, 2003; 169(6): 2076–2083.CrossRefGoogle ScholarPubMed
Vasselli, J R, Yang, J C, Linehan, W M, et al. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. J Urol, 2001; 166(1): 68–72.CrossRefGoogle ScholarPubMed
Giuliani, L, Giberti, C, Martorana, G, et al. Radical extensive surgery for renal cell carcinoma: Long-term results and prognostic factors. J Urol, 1990; 143(3): 468–473; discussion, 473–474.CrossRefGoogle ScholarPubMed
Canfield, S E, Kamat, A M, Sanchez-Ortiz, R F, et al. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease (clinical stage TxN1–2M0): The impact of aggressive surgical resection on patient outcome. J Urol, 2006; 175(3Pt 1): 864–869.CrossRefGoogle ScholarPubMed
Studer, U E, Scherz, S, Scheidegger, J, et al. Enlargement of regional lymph nodes in renal cell carcinoma is often not due to metastases. J Urol, 1990; 144(2 Pt 1): 243–245.CrossRefGoogle Scholar
Minervini, A, Lilas, L, Morelli, G, et al. Regional lymph node dissection in the treatment of renal cell carcinoma: Is it useful in patients with no suspected adenopathy before or during surgery?BJU Int, 2001; 88(3): 169–172.CrossRefGoogle ScholarPubMed
Clayman, R V, Kavoussi, L R, Figenshau, R S, et al. Laparoscopic nephroureterectomy: Initial clinical case report. J Laparoendosc Surg, 1991; 1(6): 343–349.CrossRefGoogle ScholarPubMed
Permpongkosol, S, Chan, D Y, Link, R E, et al. Long-term survival analysis after laparoscopic radical nephrectomy. J Urol, 2005; 174(4 Pt 1): 1222–1225.CrossRefGoogle ScholarPubMed
Chan, D Y, Cadeddu, J A, Jarrett, T W, et al. Laparoscopic radical nephrectomy: Cancer control for renal cell carcinoma. J Urol, 2001; 166(6): 2095–2100.CrossRefGoogle ScholarPubMed
Portis, A J, Yan, Y, Landman, J, et al. Long-term followup after laparoscopic radical nephrectomy. J Urol, 2002; 167(3): 1257–1262.CrossRefGoogle ScholarPubMed
Saika, T, Ono, Y, Hattori, R, et al. Long-term outcome of laparoscopic radical nephrectomy for pathologic T1 renal cell carcinoma. Urology, 2003; 62(6): 1018–1023.CrossRefGoogle ScholarPubMed
Gill, I S, Meraney, A M, Schweizer, D K, et al. Laparoscopic radical nephrectomy in 100 patients. Cancer, 2001; 92(7): 1843–1855.3.0.CO;2-W>CrossRefGoogle ScholarPubMed
Janetschek, G, Jeschke, K, Peschel, R, et al. Laparoscopic surgery for stage T1 renal cell carcinoma: Radical nephrectomy and wedge resection. Eur Urol, 2000; 38(2): 131–138.CrossRefGoogle ScholarPubMed
Matin, S F, Abreu, S, Ramani, A, et al. Evaluation of age and comorbidity as risk factors after laparoscopic urological surgery. J Urol, 2003; 170(4 Pt 1): 1115–1120.CrossRefGoogle ScholarPubMed
Fazeli-Matin, S, Gill, I S, Hsu, T H, et al. Laparoscopic renal and adrenal surgery in obese patients: Comparison to open surgery. J Urol, 1999; 162(3 Pt 1): 665–669.CrossRefGoogle ScholarPubMed
Meraney, A M, Gill, I S. Financial analysis of open versus laparoscopic radical nephrectomy and nephroureterectomy. J Urol, 2002; 167(4): 1757–1762.CrossRefGoogle ScholarPubMed
Matin, S F and Gill, I S. Laparoscopic radical nephrectomy: Retroperitoneal versus transperitoneal approach. Curr Urol Reports, 2002; 3(2): 164–171.CrossRefGoogle ScholarPubMed
Gill, I S, Strzempkowski, B, Kaouk, J H, et al. Prospective randomized comparison: Transperitoneal vs retropritoneal laparoscopic radical nephrectomy [abstract]. J Endourol, 2002; 167(4): 19.Google Scholar
Wolf, J S Jr., Moon, T D, Nakada, S Y. Hand assisted laparoscopic nephrectomy: Comparison to standard laparoscopic nephrectomy [see comments]. J Urol, 1998; 160(1): 22–27.CrossRefGoogle Scholar
Matin, S F, Dhanani, N, Acosta, M, et al. Conventional and hand-assisted laparoscopic radical nephrectomy: A comparative analysis of 271 cases. J Endourol, 2006; 20: 891–894.CrossRefGoogle ScholarPubMed
Wolf, J S Jr., Marcovich, R, Merion, R M, et al. Prospective, case matched comparison of hand assisted laparoscopic and open surgical live donor nephrectomy. J Urol, 2000; 163(6): 1650–1653.CrossRefGoogle ScholarPubMed
Cohen, D D, Matin, S F, Steinberg, J R, et al. Evaluation of the intact specimen in patients who undergo laparoscopic radical nephrectomy for clinically localized renal cell carcinoma identifies a subset of patients at increased risk for recurrence. J Urol, 2005;173(5): 1487–1491.CrossRefGoogle Scholar
Pearlstone, D B, Feig, B W, and Mansfield, P F. Port site recurrences after laparoscopy for malignant disease. Semin Surg Oncol, 1999; 16(4): 307–312.3.0.CO;2-5>CrossRefGoogle ScholarPubMed
Tsivian, A, Shtabsky, A, Issakov, J, et al. The effect of pneumoperitoneum on dissemination and scar implantation of intra-abdominal tumor cells. J Urol, 2000; 164(6): 2096–2098.CrossRefGoogle ScholarPubMed
Tsivian, A, Sidi, A A. Port site metastases in urological laparoscopic surgery. J Urol, 2003; 169(4): 1213–1218.CrossRefGoogle ScholarPubMed
Chen, Y-T, Yang, SSD, Hsieh, C-H, et al. Hand port-site metastasis of renal-cell carcinoma following hand-assisted laparoscopic radical nephrectomy: Case report. J Endourol, 2003; 17(9): 771–775.CrossRefGoogle ScholarPubMed
Palmer, J M, Swanson, D A. Conservative surgery in solitary and bilateral renal carcinoma: Indications and technical considerations. J Urol, 1978; 120(1): 113–117.CrossRefGoogle ScholarPubMed
Novick, A C, Gephardt, G, Guz, B, et al. Long-term follow-up after partial removal of a solitary kidney [see comments]. N Engl J Med, 1991; 325(15): 1058–1062.CrossRefGoogle Scholar
Belldegrun, A, Tsui, K H, Kernion, J B, et al. Efficacy of nephron-sparing surgery for renal cell carcinoma: Analysis based on the new 1997 tumor-node-metastasis staging system. J Clin Oncol, 1999; 17(9): 2868–2875.CrossRefGoogle ScholarPubMed
Herr, H W. Partial nephrectomy for unilateral renal carcinoma and a normal contralateral kidney: 10-year followup. J Urol, 1999; 161(1): 33–34; discussion, 34–35.CrossRefGoogle Scholar
Fergany, A F, Hafez, K S, Novick, A C. Long-term results of nephron sparing surgery for localized renal cell carcinoma: 10-year followup. J Urol, 2000; 163(2): 442–445.CrossRefGoogle ScholarPubMed
Patard, J J, Shvarts, O, Lam, J S, et al. Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol, 2004; 171(6 Pt 1): 2181–2185.CrossRefGoogle ScholarPubMed
Clark, P E, Schover, L R, Uzzo, R G, et al. Quality of life and psychological adaptation after surgical treatment for localized renal cell carcinoma: Impact of the amount of remaining renal tissue. Urology, 2001; 57(2): 252–256.CrossRefGoogle ScholarPubMed
Ficarra, V, Novella, G, Sarti, A, et al. Psycho-social well-being and general health status after surgical treatment for localized renal cell carcinoma. Int Urol Nephrol, 2002; 34(4): 441–446.CrossRefGoogle ScholarPubMed
Shinohara, N, Harabayashi, T, Sato, S, et al. Impact of nephron-sparing surgery on quality of life in patients with localized renal cell carcinoma. Eur Urol, 2001; 39(1): 114–119.CrossRefGoogle ScholarPubMed
Lau, W, Blute, M, and Zincke, H. Matched comparison of radical nephrectomy versus elective nephron-sparing surgery for renal cell carcinoma (RCC): evidence for increased renal failure rate on long term followup (>10 years). J Urol, 2000; 163(4): S153.Google Scholar
Castilla, E A, Liou, L S, Abrahams, N A, et al. Prognostic importance of resection margin width after nephron-sparing surgery for renal cell carcinoma. Urology, 2002; 60(6): 993–997.CrossRefGoogle ScholarPubMed
Sutherland, S E, Resnick, M I, Maclennan, G T, et al. Does the size of the surgical margin in partial nephrectomy for renal cell cancer really matter?J Urol, 2002; 167(1): 61–64.CrossRefGoogle ScholarPubMed
Piper, N Y, Bishoff, J T, Magee, C, et al. Is a 1-cm margin necessary during nephron-sparing surgery for renal cell carcinoma?Urology, 2001; 58(6): 849–852.CrossRefGoogle ScholarPubMed
Gill, I S, Matin, S F, Desai, M M, et al. Comparative analysis of laparoscopic versus open partial nephrectomy for renal tumors in 200 patients. J Urol, 2003; 170(1): 64–68.CrossRefGoogle ScholarPubMed
Steinberg, A P, Gill, I S, Strzempkowski, B, et al. 3-year follow-up of laparoscopic renal cryoablation in 25 patients (abstract). J Urol, 2001; 167(4): 166.Google Scholar
Gervais, D A, McGovern, F J, Arellano, R S, et al. Renal cell carcinoma: Clinical experience and technical success with radio-frequency ablation of 42 tumors. Radiology, 2003; 226(2): 417–424.CrossRefGoogle ScholarPubMed
Matin, S F, Ahrar, K, Cadeddu, J A, et al. Residual and recurrent disease following renal energy-ablative therapy: Implications for management – a multi-institutional study. J Urol, 2006; 176: 1973–1977.CrossRefGoogle Scholar
Blute, M L, Leibovich, B C, Lohse, C M, et al. The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. BJU Int, 2004; 94(1): 33–41.CrossRefGoogle Scholar
Kallman, D A, King, B F, Hattery, R R, et al. Renal vein and inferior vena cava tumor thrombus in renal cell carcinoma: CT, US, MRI and venacavography. J Comput Assist Tomogr, 1992; 16(2): 240–247.CrossRefGoogle ScholarPubMed
Glazer, A and Novick, A C. Preoperative transesophageal echocardiography for assessment of vena caval tumor thrombi: A comparative study with venacavography and magnetic resonance imaging. Urology, 1997; 49(1): 32–34.CrossRefGoogle ScholarPubMed
Glazer, A A and Novick, A C. Long-term followup after surgical treatment for renal cell carcinoma extending into the right atrium. J Urol, 1996; 155(2): 448–450.CrossRefGoogle ScholarPubMed
Naitoh, J, Kaplan, A, Dorey, F, et al. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: Long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy. J Urol, 1999; 162(1): 46–50.CrossRefGoogle ScholarPubMed
Nesbitt, J C, Soltero, E R, Dinney, C P, et al. Surgical management of renal cell carcinoma with inferior vena cava tumor thrombus. Ann Thorac Surg, 1997; 63(6): 1592–1600.CrossRefGoogle ScholarPubMed
Moinzadeh, A and Libertino, J A. Prognostic significance of tumor thrombus level in patients with renal cell carcinoma and venous tumor thrombus extension. Is all T3b the same?J Urol, 2004; 171(2 Pt 1): 598–601.CrossRefGoogle Scholar
Han, K R, Bui, M H, Pantuck, A J, et al. TNM T3a renal cell carcinoma: Adrenal gland involvement is not the same as renal fat invasion. J Urol, 2003; 169(3): 899–903.CrossRefGoogle Scholar
Flanigan, R C, Mickisch, G, Sylvester, R, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: A combined analysis. J Urol, 2004; 171(3): 1071–1076.CrossRefGoogle ScholarPubMed
Wood, C G. The role of cytoreductive nephrectomy in the management of metastatic renal cell carcinoma. Urol Clin North Am, 2003; 30(3): 581–588.CrossRefGoogle ScholarPubMed
Walther, M M, Lyne, J C, Libutti, S K, et al. Laparoscopic cytoreductive nephrectomy as preparation for administration of systemic interleukin-2 in the treatment of metastatic renal cell carcinoma: A pilot study. Urology, 1999; 53(3): 496–501.CrossRefGoogle ScholarPubMed
Matin, S F, Madsen, L and Wood, C G. Laparoscopic cytoreductive nephrectomy: The M.D. Anderson cancer center experience. Urol, 2006; 68: 528–532.CrossRefGoogle Scholar
Kavolius, J P, Mastorakos, D P, Pavlovich, C, et al. Resection of metastatic renal cell carcinoma. J Clin Oncol, 1998; 16(6): 2261–2266.CrossRefGoogle ScholarPubMed
Lam, J S, Shvarts, O, Leppert, J T, et al. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol, 2005; 174(2): 466–472.CrossRefGoogle ScholarPubMed
Clark, J I, Atkins, M B, Urba, W J, et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: A cytokine working group randomized trial. J Clin Oncol, 2003; 21(16): 3133–3140.CrossRefGoogle ScholarPubMed
Lam, J S, Leppert, J T, Belldegrun, A S, et al. Adjuvant therapy of renal cell carcinoma: Patient selection and therapeutic options. BJU Int, 2005; 96(4): 483–488.CrossRefGoogle ScholarPubMed
Messing, E M, Manola, J, Wilding, G, et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: An Eastern Cooperative Oncology Group/Intergroup trial [see comment]. J Clin Oncol, 2003; 21(7): 1214–1222.CrossRefGoogle Scholar
Pizzocaro, G, Piva, L, Colavita, M, et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: A multicentric randomized study. J Clin Oncol, 2001; 19(2): 425–431.CrossRefGoogle ScholarPubMed
Jocham, D, Richter, A, Hoffmann, L, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomised controlled trial. Lancet, 2004; 363(9409): 594–599.CrossRefGoogle ScholarPubMed
Wood, C G, Escudier, B, Gorelov, S, et al. A multicenter randomized study of adjuvant heat-shock protein peptide-complex 96 (HSPPC-96) vaccine in patients with high-risk of recurrence after nephrectomy for renal cell carcinoma (RCC) – a preliminary report. J Clin Oncol, 2004; 22(14S): 2618.CrossRefGoogle Scholar
Daliani, D D, Papandreou, C N, Thall, P F, et al. A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma. Cancer, 2002; 95(4): 758–765.CrossRefGoogle ScholarPubMed
Clark, P E, Hall, M C, Miller, A, et al. Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma. Urology, 2004; 63(6): 1061–1065.CrossRefGoogle ScholarPubMed
Amato, R J. Thalidomide therapy for renal cell carcinoma. Crit Rev Oncol Hematol, 2003; 46(65): 27.CrossRefGoogle ScholarPubMed
Sanchez-Ortiz, R, Tamboli, P, Lozano, M L, et al. Adjuvant thalidomide improves disease specific survival for patients with renal cell carcinoma at high risk for relapse following surgery. J Clin Oncol, 2006; 24(18S): 14586.Google Scholar
Clinical Trials Support Unit C. ECOG2805: A randomized, double blind Phase III trial of adjuvant sunitinib versus sorafenib versus placebo in patients with resected renal cell carcinoma. http://www.ctsu.org; accessed Aug. 8, 2006.
Pyrhonen, S, Salminen, E, Ruutu, M, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol, 1999; 17(9): 2859–2867.CrossRefGoogle ScholarPubMed
Rini, B I, Vogelzang, N J, Dumas, M C, Wet al. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol, 2000; 18(12): 2419–2426.CrossRefGoogle ScholarPubMed
Waters, J S, Moss, C, Pyle, L, et al. Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma. Br J Cancer, 2004; 91(10): 1763–1768.CrossRefGoogle ScholarPubMed
Freed, S Z, Halperin, J P and Gordon, M. Idiopathic regression of metastases from renal cell carcinoma. J Urol, 1977; 118(4): 538–542.CrossRefGoogle ScholarPubMed
Fyfe, G, Fisher, R I, Rosenberg, S A, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol, 1995; 13(3): 688–696.CrossRefGoogle ScholarPubMed
Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: Early results of a randomised controlled trial [see comments]. Lancet, 1999; 353(9146): 14–17.CrossRef
Negrier, S, Caty, A, Lesimple, T, et al. Treatment of patients with metastatic renal arcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. J Clin Oncol, 2000; 18(24): 4009–4015.CrossRefGoogle ScholarPubMed
George, D J and Kaelin, W G Jr.The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. N Engl J Med, 2003; 349(5): 419–421.CrossRefGoogle ScholarPubMed
Yang, J C, Haworth, L, Sherry, R M, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med, 2003; 349(5): 427–434.CrossRefGoogle ScholarPubMed
Rini, B I, Halabi, S, Taylor, J, et al. Cancer and Leukemia Group B 90206: A randomized Phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res, 2004; 10(8): 2584–2586.CrossRefGoogle Scholar
Escudier, B, Eisen, T, Stadler, W M,et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med, 2007; 356(2): 125–134.CrossRefGoogle Scholar
Motzer, R J, Hutson, T E, Tomczak, P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med, 2007; 356(2): 115–124.CrossRefGoogle ScholarPubMed
Herbst, R S, Johnson, D H, Mininberg, E, et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol, 2005; 23(11): 2544–2555.CrossRefGoogle ScholarPubMed
Druker, B J, Schwartz, L, Marion, S, et al. Phase II trial of ZD 1839 (Iressa), and EGF receptor inhibitor, in patients with renal cell carcinoma. Proc Am Soc Clin Oncol, 2002; 21: 720.Google Scholar
Dawson, N A, Guo, C, Zak, R. A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma. Clin Cancer Res, 2004; 10: 7812–7819.CrossRefGoogle ScholarPubMed
Hudes, G, Carducci, M, Tomczak, P, et al. Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med, 2007; 356(22): 2271–2281.CrossRefGoogle ScholarPubMed
Drachenberg, D, Childs, R W. Allogeneic stem cell transplantation as immunotherapy for renal cell carcinoma: From immune enhancement to immune replacement. Urol Clin North Am, 2003; 30: 611–622.CrossRefGoogle ScholarPubMed
Childs, R, Chernoff, A, Contentin, N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med, 2000; 343(11): 750–758.CrossRefGoogle ScholarPubMed
Childs, R W, Clave, E, Tisdale, J, et al. Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: Evidence for a graft-versus-tumor effect. J Clin Oncol, 1999; 17(7): 2044–2049.CrossRefGoogle ScholarPubMed
Escudier, B, Droz, J P, Rolland, F, et al. Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: A Phase II study of the Genitourinary Group of the French Federation of Cancer Centers. J Urol, 2002; 168(3): 959–961.CrossRefGoogle ScholarPubMed
Rashid, M H, Welsh, C T, Bissada, N K, et al. Complete response to Adriamycin and ifosfamide in a patient with sarcomatoid renal cell carcinoma. Am J Clin Oncol, 2005; 28(1): 107–108.CrossRefGoogle Scholar
Nanus, D M, Garino, A, Milowsky, M I, et al. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer, 2004; 101(7): 1545–1551.CrossRefGoogle ScholarPubMed
Milowsky, M I, Rosmarin, A, Tickoo, S K, et al. Active chemotherapy for collecting duct carcinoma of the kidney: A case report and review of the literature. Cancer, 2002; 94(1): 111–116.CrossRefGoogle ScholarPubMed
Muacevic, A, Siebels, M, Tonn, J C, et al. Treatment of brain metastases in renal cell carcinoma: Radiotherapy, radiosurgery, or surgery?World J Urol, 2005; 23(3): 180–184.CrossRefGoogle ScholarPubMed
Fakih, M, Schiff, D, Erlich, R, et al. Intramedullary spinal cord metastasis (ISCM) in renal cell carcinoma: A series of six cases. Ann Oncol, 2001; 12(8): 1173–1177.CrossRefGoogle ScholarPubMed
Goyal, L K, Suh, J H, Reddy, C A, et al. The role of whole brain radiotherapy and stereotactic radiosurgery on brain metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys, 2000; 47(4): 1007–1012.CrossRefGoogle ScholarPubMed
Wallace, S, Granmayeh, M, Santos, L A, et al. Arterial occlusion of pelvic bone tumors. Cancer, 1979; 43(1): 322–328.3.0.CO;2-Q>CrossRefGoogle ScholarPubMed
Sweeney, P, Wood, C G, Pisters, L L, et al. Surgical management of renal cell carcinoma associated with complex inferior vena caval thrombi. Urol Oncol, 2003; 21(5): 327–333.CrossRefGoogle ScholarPubMed
Swanson, D A, Johnson, D E, Eschenbach, A C, et al. Angioinfarction plus nephrectomy for metastatic renal cell carcinoma – an update. J Urol, 1983; 130(3): 449–452.CrossRefGoogle ScholarPubMed
Motzer, R J, Bacik, J, Murphy, B A, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol, 2002; 20(1): 289–296.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×